Adaptive Biotech HR chief sells 115K shares
Adaptive Biotechnologies’ Chief People Officer exercised options and sold over 115,000 shares under a pre-arranged Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp (ADPT) reported that Chief People Officer Francis Lo exercised employee stock options for 105,560 shares of common stock on September 16, 2026, at exercise prices between $3.99 and $12.14 per share, and on the same day sold 115,406 shares of common stock in market transactions.
The sales, made at weighted average prices of $28.02 and $28.57 per share within disclosed price ranges, were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025. An additional 2,500 shares are reported as indirectly held through Lo’s spouse.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
11 txns
Insider
LO FRANCIS
Role
Chief People Officer
Sold
115,406 shs ($3.24M)
Approx. gross sale proceeds
$3.24M
Approx. exercise cost
$1.01M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F4 | 53,091 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) F1, F5 | 13,398 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) F1, F6 | 15,629 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) F1, F7 | 23,442 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 53,091 | $12.14 | $645K |
| Exercise | Common Stock F1 | 13,398 | $8.46 | $113K |
| Exercise | Common Stock F1 | 15,629 | $3.99 | $62K |
| Exercise | Common Stock F1 | 23,442 | $8.12 | $190K |
| Sale | Common Stock F1, F2 | 107,537 | $28.02 | $3.01M |
| Sale | Common Stock F1, F3 | 7,869 | $28.57 | $225K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 272,046 contracts (Direct);
Common Stock — 220,867 shares (Direct);
Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))
Footnotes (7)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.49 to $28.67, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The option is fully vested and exercisable.
- F5. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F6. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F7. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Key Figures
Shares acquired via option exercises: 105,560 shares
Shares sold: 115,406 shares
Weighted average sale price (first block): $28.02 per share
+4 more
7 metrics
Shares acquired via option exercises
105,560 shares
Employee stock options exercised into common stock on September 16, 2026
Shares sold
115,406 shares
Common stock sales on September 16, 2026
Weighted average sale price (first block)
$28.02 per share
Sales within a range of $27.49–$28.48
Weighted average sale price (second block)
$28.57 per share
Sales within a range of $28.49–$28.67
Option exercise prices
$12.14, $8.46, $3.99, $8.12 per share
Exercise prices for options converted into common stock
Rule 10b5-1 plan adoption date
September 15, 2025
Date the trading plan governing these transactions was adopted
Indirectly held shares
2,500 shares
Common stock held through the insider’s spouse
Key Terms
Rule 10b5-1 trading plan, weighted average price, continuous service, fully vested and exercisable
4 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
continuous service other
"with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested."
fully vested and exercisable financial
"The option is fully vested and exercisable."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ADPT’s Chief People Officer report on September 16, 2026?
Francis Lo reported exercising employee stock options for 105,560 shares of Adaptive Biotechnologies common stock and selling 115,406 shares of common stock in market transactions on September 16, 2026.
Were the ADPT insider’s trades made under a Rule 10b5-1 plan?
Yes. All transactions reported were effected under a Rule 10b5-1 trading plan adopted by Francis Lo on September 15, 2025, as disclosed in the filing footnotes.
What option exercise prices were involved in the ADPT Form 4 filing?
Francis Lo exercised employee stock options covering 105,560 shares of Adaptive Biotechnologies common stock at exercise prices of $12.14, $8.46, $3.99, and $8.12 per share on September 16, 2026.
Does the ADPT Form 4 show any indirect holdings for the insider?
Yes. The filing reports 2,500 shares of Adaptive Biotechnologies common stock held indirectly by Francis Lo through his spouse, identified as You Jin Lee.
How many ADPT option exercises are reported in this Form 4?
The filing reports four separate employee stock option exercises by Francis Lo, covering a total of 105,560 shares of Adaptive Biotechnologies common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
